Amgen reports mixed results of Phase III heart failure trial
Omecamtiv mecarbil targets the contractile mechanisms of the heart. Credit: Robina Weermeijer on Unsplash.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more